Business Wire

Morrow Sodali Bolsters its Debt Services Team with Key Industry Hires

Share

Morrow Sodali announced today that Debt Capital Markets industry experts Damian Watkin, Damir Hadžiosmanović, Ken Abela and Tina Siu, have joined the firm as part of a global strategy to strengthen its bonds-related services offering.

The team, which provides 50+ years of combined experience working on over 800 debt-related deals, joins Morrow Sodali from D.F. King and will be based in London and Hong Kong, bolstering the firm’s global presence in Debt Services. They will work alongside leading in-house expert Pia Gowland who from now on will oversee Morrow Sodali’s Debt Services activities in the Americas.

Damian Watkin, who joins Morrow Sodali as a Senior Director in the firm’s London office, brings 20 years’ experience in the capital markets industry working with global financial institutions, corporate and sovereign issuers, with extensive expertise in executing liability management and debt restructuring transactions and researching ownership in capital structures. In his previous role at D.F. King, Mr. Watkin built and led the firm’s bonds business outside of the US market, working with a broad range of debt issuers, and their advisors, in some of the largest or highest profile transactions of recent years.

“We are very excited to join the entrepreneurial and client-focused team at Morrow Sodali and be able to offer a seamless service from a truly global and technology-led execution platform to bond issuers and their advisers,” said Mr. Watkin. “Morrow Sodali now has a global footprint, with experienced execution professionals based in Asia, Europe and the Americas.”

Joining Mr. Watkin in London as a Director, Damir Hadžiosmanović has nearly 20 years’ experience in working with corporate and sovereign issuers, assisting them in executing various liability management transactions and bondholder identifications, as well as debt restructurings and schemes of arrangement.

Ken Abela, who joins Morrow Sodali as a Director, brings nearly 20 years’ experience, of which 17 years in Asia, in assisting corporate and sovereign issuers in executing liability management and debt restructuring transactions. Mr. Abela will be based in Hong Kong and will be responsible for strengthening the firm’s Debt Services offering across Asia Pacific markets.

“We are looking forward to expanding Morrow Sodali’s debt-related services in Asia, providing bond issuers and their advisors in the region with an experienced local point of contact, with the ability to assist with transactions and provide advice to practitioners in their own time zone,” said Mr. Abela.

Joining Mr. Abela in Hong Kong, Tina Siu has assisted in providing D.F. King’s debt-related activities led by Mr. Abela, with a strong track record of supporting bond issuers in executing liability management transactions across Asian markets. Prior to D.F. King, Ms. Siu worked with financial institutions focusing on debt market research as well as conducting financial analysis for corporate clients.

Morrow Sodali Global Corporate Director Giulio Pediconi commented: “We are delighted to welcome such an experienced team within the Morrow Sodali family. With the global expansion of corporate debt markets, our combined expertise across our dedicated hubs in New York, London and Hong Kong will enable us to expand our services and offer our clients a truly global coverage in this key market.”

About Morrow Sodali

Morrow Sodali is a leading provider of strategic advice and shareholder and bondholder services to corporate and sovereign clients around the world. The firm provides corporate boards and executives with strategic advice and services relating to corporate governance, shareholder and bondholder communication and engagement, capital markets intelligence, proxy solicitation, shareholder activism, mergers and acquisitions and debt-related transactions.

From headquarters in New York and London, and offices and partners in major capital markets, Morrow Sodali serves more than 700 corporate clients in 40 countries, including many of the world’s largest multinational corporations. In addition to listed and private companies, its clients include mutual funds, ETFs, stock exchanges and membership associations.

For further information about Morrow Sodali, please visit www.morrowsodali.com

Contact information

New York
Pia Gowland / Gerry Davis
p.gowland@morrowsodali.com
g.davis@morrowsodali.com
Phone:
PG: +1 212 324 4934
GD: +1 203 658 9377

London
Damian Watkin / Damir Hadžiosmanović
d.watkin@morrowsodali.com
d.hadziosmanovic@morrowsodali.com
Phone:
DW: +44 (0)20 7355 0628
DH: +44 (0)20 7355 0615

Hong Kong
Ken Abela
k.abela@morrowsodali.com
Phone: +852 2158 8404

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom